Zydus Lifesciences and Guardant Health, a leading precision oncology company, have signed a co-marketing agreement to jointly promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal. The tests to be promoted include the Guardant360 and Guardant360 TissueNext tests for comprehensive genomic profiling and the Guardant360 Response test for monitoring response to treatment.
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region. By combining resources and expertise, both organisations aim to empower oncologists with the necessary tools to help inform treatment decisions for patients with advanced cancer.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.